AU2020411442B2 - Aqueous suspension composition containing sirolimus or salt thereof - Google Patents

Aqueous suspension composition containing sirolimus or salt thereof

Info

Publication number
AU2020411442B2
AU2020411442B2 AU2020411442A AU2020411442A AU2020411442B2 AU 2020411442 B2 AU2020411442 B2 AU 2020411442B2 AU 2020411442 A AU2020411442 A AU 2020411442A AU 2020411442 A AU2020411442 A AU 2020411442A AU 2020411442 B2 AU2020411442 B2 AU 2020411442B2
Authority
AU
Australia
Prior art keywords
sirolimus
salt
composition
aqueous suspension
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020411442A
Other languages
English (en)
Other versions
AU2020411442A1 (en
Inventor
Ayaka AKUTAGAWA
Toyomi FUJISAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of AU2020411442A1 publication Critical patent/AU2020411442A1/en
Application granted granted Critical
Publication of AU2020411442B2 publication Critical patent/AU2020411442B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020411442A 2019-12-26 2020-12-25 Aqueous suspension composition containing sirolimus or salt thereof Active AU2020411442B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019237226 2019-12-26
JP2019-237226 2019-12-26
PCT/JP2020/048738 WO2021132565A1 (ja) 2019-12-26 2020-12-25 シロリムスまたはその塩を含有する水性懸濁組成物

Publications (2)

Publication Number Publication Date
AU2020411442A1 AU2020411442A1 (en) 2022-06-23
AU2020411442B2 true AU2020411442B2 (en) 2026-02-12

Family

ID=76575568

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020411442A Active AU2020411442B2 (en) 2019-12-26 2020-12-25 Aqueous suspension composition containing sirolimus or salt thereof

Country Status (9)

Country Link
US (1) US20230055121A1 (https=)
EP (1) EP4082544A4 (https=)
JP (2) JP7682103B2 (https=)
KR (1) KR20220122612A (https=)
CN (2) CN118340726A (https=)
AU (1) AU2020411442B2 (https=)
CA (1) CA3162626A1 (https=)
TW (1) TWI871406B (https=)
WO (1) WO2021132565A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942607A (zh) * 2023-01-13 2023-10-27 杭州微致生物科技有限公司 一种西罗莫司混悬液

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023877A2 (en) * 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
CN106420607A (zh) * 2016-11-02 2017-02-22 北京诺康达医药科技有限公司 一种西罗莫司纳米混悬剂及其制备方法
CN107334734A (zh) * 2017-07-10 2017-11-10 浙江大学 一种西罗莫司或其衍生物的眼用制剂
US20180193320A1 (en) * 2017-01-06 2018-07-12 Palvella Therapeutics Llc ANYHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
CN105073112B (zh) 2013-03-13 2017-12-29 参天制药株式会社 睑板腺功能障碍的治疗剂
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
CN105833344B (zh) * 2016-04-26 2019-04-26 青岛慧生惠众生物科技有限公司 一种可注射水凝胶在制备眼内填充物中的应用
US20200261427A1 (en) * 2019-02-20 2020-08-20 Al Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023877A2 (en) * 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
CN106420607A (zh) * 2016-11-02 2017-02-22 北京诺康达医药科技有限公司 一种西罗莫司纳米混悬剂及其制备方法
US20180193320A1 (en) * 2017-01-06 2018-07-12 Palvella Therapeutics Llc ANYHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
CN107334734A (zh) * 2017-07-10 2017-11-10 浙江大学 一种西罗莫司或其衍生物的眼用制剂

Also Published As

Publication number Publication date
WO2021132565A1 (ja) 2021-07-01
TWI871406B (zh) 2025-02-01
KR20220122612A (ko) 2022-09-02
JP7682103B2 (ja) 2025-05-23
CA3162626A1 (en) 2021-07-01
AU2020411442A1 (en) 2022-06-23
JPWO2021132565A1 (https=) 2021-07-01
US20230055121A1 (en) 2023-02-23
CN118340726A (zh) 2024-07-16
EP4082544A4 (en) 2024-01-10
JP2025111828A (ja) 2025-07-30
TW202135806A (zh) 2021-10-01
CN114845714A (zh) 2022-08-02
CN114845714B (zh) 2024-05-14
EP4082544A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
EP3096740B1 (en) Pharmaceutical composition comprising brinzolamide
EA034839B1 (ru) Офтальмологический раствор
KR102876762B1 (ko) 에피나스틴 함유 점안액
US20180169079A1 (en) Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
US5556848A (en) Ophthalmic suspension containing diflupredonate
EP3718535B1 (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
JP6903448B2 (ja) ドルゾラミドとブリモニジンを含む医薬組成物
AU2020411442B2 (en) Aqueous suspension composition containing sirolimus or salt thereof
US6274609B1 (en) Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
CN111741755B (zh) 肠胃外制剂及其用途
WO2010119942A1 (ja) レボカバスチン懸濁型点眼剤
KR20220038443A (ko) 무균 안과용 수성 플루티카손 프로피오네이트 a형 나노결정 현탁액을 제조하는 방법
EP4631498A1 (en) Eye drop-type pharmaceutical composition containing envogliflozin
RU2842860C1 (ru) Водная суспензионная композиция, содержащая сиролимус или его соль
EP3689349A1 (en) Drug containing pyridylaminoacetic acid compound
EP2827838B1 (en) Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
JP2022001606A (ja) エピナスチン又はその塩を含有する水性組成物
JPH01313429A (ja) 麦角アルカロイドを含有してなり緑内障を処置する眼用軟膏
KR101519673B1 (ko) 피레녹신을 함유하는 현탁형 수성 액제
CA3220425A1 (en) Pharmaceutical composition, and aprepitant injection and freeze-dried powder injection
EA051764B1 (ru) Офтальмологическая композиция, содержащая левофлоксацин и кеторолак, способ ее получения и ее применение
KR20250059467A (ko) 비결핵성 항산균 감염의 치료 방법
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
HK40018890B (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40018890A (en) Ophthalmic compositions containing a nitric oxide releasing prostamide